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Background: Women in sub-Saharan Africa are disproportionately affected by high rates of HIV, yet relatively few
products exist for female-initiated HIV prevention. New antiretroviral (ARV)-based prevention options could present
opportunities for women to expand their HIV prevention choices; however, acceptability and adherence play a key
role in the effectiveness of these products and implementation is still in early stages. To better understand which
HIV prevention options might best serve women in sub-Saharan Africa, how and why, this review will explore
qualitative evidence from clinical trials and implementation studies alike using a meta-ethnographic approach to
synthesise data and interpret results.
Methods/design: This systematic review will use a meta-ethnographic approach to analyse qualitative data extracted
from multiple studies featuring actual use of female-initiated technologies for HIV prevention. The search strategy will
be applied in seven databases and papers will be selected using strict inclusion and exclusion criteria. The review will
closely follow the guidance set forth by preferred reporting items for systematic reviews and meta-analyses (PRISMA)
and Centre for Reviews Dissemination (CRD) where the guidance applies to qualitative data. Two reviewers will review
all papers during the paper selection phase, with consultation from a third reviewer to confirm consensus. All papers
included in the review will be read and analysed by two reviewers. The final analysis will be conducted by three
primary reviewers with additional input from all other authors.
Discussion: With new HIV prevention technologies currently in early implementation phases and still more on the
horizon, there is much to learn about how best these products may be delivered. A review such as this could help to
inform the real-world implementation of the next wave of new HIV prevention technologies such as ARV-based oral
pre-exposure prophylaxis (PrEP).Background
New HIV infections in sub-Saharan Africa persist at high
rates where women, in particular, are disproportionately
affected [1]. In South Africa, a survey published by the
Human Sciences Research Council in 2012 estimated
the national prevalence rates among women between the
ages of 20 and 49 to be between 17.4 and 31.6 % [2].* Correspondence: reakle@wrhi.ac.za
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field only so far, but to further reduce new infections,
new options for prevention are needed.
There are several approaches men and women can take
to prevent the acquisition or transmission of HIV. Cur-
rently, these include the following: the use of male or fe-
male condoms; medical male circumcision; or the use of
post-exposure prophylaxis (PEP), an antiretroviral (ARV)
drug-based regimen given after suspected exposure to
HIV. The majority of these prevention options, aside from
PEP, are either entirely or partially controlled by men, oris distributed under the terms of the Creative Commons Attribution 4.0
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Eakle et al. Systematic Reviews  (2015) 4:111 Page 2 of 6their use is dependent upon male acceptance. Male con-
doms require mutual agreement for use, and while the fe-
male condom can be initiated by women, it difficult for
them to do so covertly. Additionally, research has sug-
gested that female condoms are often difficult to access,
and not always acceptable or easy to use [3]. PEP has
typically only been available or accessible for specific
circumstances, such as post-rape care [4], and the lim-
ited implementation suggests there may be significant
intervention capacity issues relating to the training and
education of healthcare providers [4, 5]. The dia-
phragm has been tested as an option for preventing
HIV infection, and shown to have no effect [6], al-
though efforts have been renewed to revive it as an
option by redesigning the product and adding a micro-
bicide. Studies published in the last 5 years [7, 8]
indicate that ARV-based HIV treatment has also been
shown to have a powerful secondary prevention effect
by the suppression of an infected individual’s viral
load; however, the population-level impact of this
will take time and is unlikely to control the epidemic
on its own [9].
A new primary prevention option utilising ARV-based
medication has shown significant promise. Development
of a variety of products (including pills, intravaginal mi-
crobicide gels, films and intravaginal rings) has yielded a
new first-generation option in the form of a daily pill-
based regimen, called pre-exposure prophylaxis (PrEP).
Six recent clinical trials testing oral PrEP have shown
varying levels of overall efficacy [10–13], from 44 to 75 %.
At present, however, the indication is currently only regis-
tered in the USA. The varying degrees of efficacy from the
oral PrEP trials can mostly be attributed to adherence, or
consistent and correct use of the products [14]. The FEM-
PrEP trial, consisting only of women, was stopped for
futility, while the VOICE trial was partially stopped for fu-
tility, with the final arm continuing to a flat result [15, 16].
These findings have caused researchers and implementers
alike to question whether adherence-dependent ARV-
based prevention options would actually be effectively
taken up by women and make a significant contribution
to HIV prevention. Analyses of qualitative and mixed
method research from these trials are underway, along
with additional follow-up studies to better understand
why women did not use the products. Two papers already
published on this area have revealed important insights as
to the reasons women did not use the products, including
the following: misaligned incentives for participating in
the trials (money and access to better services); ambiva-
lence about the research resulting in non-use of the
products; a lack of understanding of the need to accurately
report actual product use; and misperceptions of personal
risk of HIV [17, 18]. This has shown that non-use of the
products often had little to do with the productsthemselves and more to do with contextual issues, which
may mean that oral PrEP could still be a viable prevention
option if offered to suitably motivated users. This perspec-
tive is reinforced by recent results from the FACTS001
trial, which evaluated the efficacy of tenofovir-based intra-
vaginal microbicide gel and established the gel not to
be efficacious in preventing HIV acquisition, largely as
a result of complex behavioural/social factors, as well
as possible biological ones [19].
Given the complexities highlighted in the PrEP efficacy
trials about delivering and implementing new prevention
options, it is important to understand women’s perspec-
tives and what factors determine the use of emerging
biomedical technologies. This is essential not only to
understand how existing HIV prevention options may be
better implemented, but also to inform the delivery of
the next wave of technologies, such as oral PrEP, as
well as other new products further upstream in the de-
velopment pipeline, such as vaginal rings containing
microbicides and injectables. To date, a number of
studies have explored the acceptability of HIV preven-
tion technologies, including those already licenced for
widespread use and those in development or clinical
trial phases, as well as other contextual factors that
function as motivators or barriers to their use. Studies
producing qualitative data, like those stemming from
the failed oral PrEP trials, are imperative for under-
standing what people think, as well as how and why
they make decisions regarding uptake of HIV preven-
tion options.
This systematic literature review will explore, synthe-
sise, interpret and present the key factors that motivate
or deter uptake and use of prevention technologies for
women in sub-Saharan Africa. Such a review can help to
inform the development and rollout of new technologies
as they become available. This review will focus on
female-initiated technologies, which are those women
administer themselves, and can be technologies already
available in the market or in the development phase.
Data included in the review will be drawn from studies
of actual product use, rather than hypothetical investiga-
tions. Technologies included in the review will include
the following: PEP, PrEP, vaginal microbicides, the dia-
phragm and the female condom. While the diaphragm is
not currently an accepted, efficacious method for pre-
venting HIV, the research conducted around experiences
with use will be included in this review as these may
provide transferable insights into other product use.
Qualitative research is best suited to the exploration of
personal experience and decision making. Given its
focus on the motivations and barriers to the uptake and
use of technologies, the review will focus on the synthe-
sis and analysis of qualitative data only, utilising a meta-
ethnographic approach.
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This is a systematic review using a meta-ethnographic
approach to analysis. As such, the review will include
only qualitative data extracted from studies identified
through intensive, systematic searches, and will closely
follow the guidance set forth by the preferred report-
ing items for systematic reviews and meta-analyses
(PRISMA) statement and the Centre for Reviews and
Dissemination (CRD). This review has not been regis-
tered on the international database of prospectively
registered systematic reviews in health and social care
(PROSPERO) as since it is a review of qualitative
evidence, it does not qualify. As a result, there is no
PROSPERO number associated with this review.
The primary objective of this review is to identify and
understand the motivations and barriers affecting uptake
and use of female-initiated, primary biomedical HIV pre-
vention technologies for women in sub-Saharan Africa.
The review will incorporate the following secondary
objectives:
 To identify types of studies from which data are
extracted (e.g. stand-alone qualitative/social science,
implementation or service delivery evaluation, or
clinical trials)
 To describe elements of uptake and use of
specified technologies by sub-population
(e.g. female sex workers, victims of rape,
or young women)
 To describe factors that influence uptake and use by
intervention
 To identify priorities for future research
Search strategy
The search strategy incorporates four primary concepts:
HIV; uptake and use; qualitative research; and sub-
Saharan Africa. Search strategy concepts have been con-
structed using an iterative process. Search terms will be
adapted across databases to account for variations in sub-
ject headings. The following databases will be included in
the search: Africa-Wide Info, CINAHL, Embase, Global
Health, MEDLINE, PsycINFO, and Web of Science. The
MEDLINE search strategy was developed as the primary
search strategy template and will be adapted for the other
databases.
Inclusion and exclusion criteria
Papers will be selected during the screening process
using the following inclusion criteria:
 Population: adult women, age 18 and above
 Intervention: female-controlled, biomedical—PrEP/
microbicides, PEP, female condom, and diaphragms
 Comparator: not relevant Outcome: narrative on the motivations or barriers
to HIV prevention uptake and use
 Study design: qualitative studies—interviews or focus
groups
 Study type: studies must be based on primary
research where products have been made available
for actual use
 Location: sub-Saharan Africa
Exclusion criteria are as follows:
 Any papers published on research occurring before
2003
 Reviews
 Any studies based on hypothetical or potential use
of products not made immediately available at the
time of the research
 Any data not from the women’s point of view as the
user
 Any research from the perspective of HIV-positive
women
 Any research based on secondary prevention
technologies or interventions (eg. PMTCT)
Papers will be excluded from the review if they do not
meet all of the criteria above. Papers will not be ex-
cluded according to a quality assessment, per se, but will
be evaluated according to principles and practices as
outlined below. There will be no limitation by language,
and grey literature will be included if identified through
the database searches or through consultation with rele-
vant experts.
The concept of experience of actual use is central to
this review. As such, we will include data from studies
conducted in both trial and implementation settings. It
may be argued that incentives could be quite different in
a trial setting where participants are paid to come to a
clinic as compared to a ‘real-world’ setting where pa-
tients come when they feel they need to. From this per-
spective, trial participants could be more incentivised to
attend the clinic. However, in the case where new pre-
vention options proven to protect against HIV are avail-
able, the accessibility of the product or intervention may
be the incentive to come to the clinic. Clearly, there are
a variety of motivators for engaging in health-related be-
haviour, which we hope to explore in the context of
female-initiated HIV prevention. In this review, we hy-
pothesise that some of the experiences of actually using
the products should be similar regardless of initial mo-
tivation. Additionally, some HIV prevention trials were
stopped early or ended with a flat result because of non-
use. In this paper, we aim to elucidate the issues leading
to non-use across both the trial and the clinic settings,
and hypothesise that reasons for non-use are likely to be
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types to highlight any differences.
The year 2003 was chosen as the cutoff point for
selecting papers as it marks the establishment of the
president’s emergency plan for AIDS relief (PEPFAR)
and the wide-scale introduction of antiretroviral therapy
(ART) for HIV treatment in Africa. With the introduc-
tion of effective medication regimens, general population
views of HIV and the means by which its transmission
could be managed began to change [20]. The rollout of
ART in Africa significantly changed the approach to the
epidemic in sub-Saharan Africa which, until this time,
largely consisted of efforts to promote condom use and
HIV testing with the aim of preventing new infections;
this had limited success as people testing HIV-positive
could not access life-saving medication. Although treat-
ment was not uniformly rolled out simultaneously in all
countries in 2003, the launch of PEPFAR and increased
access to ART renewed hope and motivation to preven-
tion efforts and is attributed to the turn of the epidemic
in Africa [21].
Screening process
All references will be uploaded into a reference manager
database and duplicates removed before starting the
paper selection process. After de-duplication, all papers
will be reviewed by title and abstract according to the in-
clusion and exclusion criteria by two reviewers. Any dis-
crepancies between reviewers will be discussed and
mediated by a third researcher. Once papers have been
selected by title and abstract, three reviewers will review
papers by full-text according to the inclusion criteria.
Decisions regarding inclusion of papers from the same
study will occur through discussion with all three re-
viewers on a case by case basis. All papers selected by
the reviewers will be discussed by all three reviewers to
reach consensus and confirm inclusion.
Data extraction, analysis and synthesis
This review will be conducted as a meta-ethnography.
This process of analysis will follow the principles set out
in Noblit and Hare [22], but will use a form of this method
as adapted more recently by several researchers [23–25].
Specifically, this adapted form of meta-ethnographic syn-
thesis allows for qualitative data collected through
methods beyond ethnography, such as interviews and
focus groups, to be combined and interpreted to derive
meaning and understanding of data across different types
of studies.
Once papers for inclusion have been finalised after full-
text review, reviewers will be assigned papers for data ex-
traction according to the data extraction tool developed
for the review. A thematic framework will also be con-
structed through the data extraction phase in an iterativefashion, with input from all reviewers. A minimum of two
reviewers will extract data from each paper; consensus will
be reached with input from the third reviewer on any dif-
ferences in extracted data. The thematic framework will
be used to build the meta-ethnographic constructs which
comprise three layers: the perspective of the participants,
the perspective of the authors, and the perspectives of the
researchers conducting this review. These layers are often
fluid and may overlap where the perspectives of the au-
thors cannot always be divided from those of the partici-
pants, but eventually, these two initial layers lead into the
construction of the final layer in which new understanding
can be developed by looking across all of the data at once.
Quality assessment
In contrast to quantitative research, there has been con-
siderable debate over how to assess the quality of quali-
tative research [26–29]. Inherent to qualitative research
is a flexible, iterative, and pluralistic process which is
guided by the context in which it is conducted and by
the research subjects themselves. Several authors have
argued that it is not typically an undertaking easily stan-
dardised by checklists, which could actually hinder the
creative nature of the work. Instead, there are accepted
practices, or fundamental principles, by which one can
analyse the research [27, 30]. An approach often adopted
is the ‘the weight of evidence review’, which first estab-
lishes elements of good research, and those elements are
then taken into account when looking across all of the
papers included in a review [31]. This enables an assess-
ment of the quality of the literature, so that the review
can be judged as a whole rather than evaluating individ-
ual elements of each paper. In this review, a combination
of the fundamental principles and weight of evidence re-
view may be employed to judge the overall level of qual-
ity of papers included.
Anticipating limitations and bias
As with any research study, the authors recognise that
there will be limitations to this particular review.
Some components of the qualitative research included
in individual studies may have been excluded from pub-
lication due to limits enforced by the publisher. Often,
in-depth descriptions of methods, and development of
the research and process through which it was under-
taken, are left out of the publications, making it difficult
to assess quality of the research process and the aware-
ness of the researchers’ positions within their own re-
search (reflexivity). Inevitably, these exclusions would
affect the potential scope of qualitative evidence avail-
able for this review.
It is possible that some research may be absent
altogether from the searchable and published literature.
Research has shown that around 44 % of conference
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pers published in journals—which is about the same rate
as for quantitative research [32]. Additionally, while this
review will not exclude grey literature, the constraints of
web-based searching and the lack of systematic, online
grey literature indexing means it is difficult to determine
whether our search has successfully captured all relevant
grey literature.
Discussion
This systematic review, using a meta-ethnographic ap-
proach for analysis, is the first of its kind to synthesise
qualitative data across a wide and complex body of lit-
erature in this subject area. The ultimate aim of this
study is to learn from research already conducted on
women’s experiences of HIV prevention technologies
and their motivations to take up and use them (and bar-
riers to doing so), in order to inform the real-world im-
plementation of the next wave of new technologies such
as oral PrEP. Ultimately, these findings can help with fu-
ture programming design, decisions and research to op-
timise delivery of existing and new HIV prevention
interventions for women across sub-Saharan Africa.
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